MAPK3 and prostate carcinoma: These data suggest a specific ARF1-mediated pathway contributing to the activation of the Raf1/MEK/ERK1/2 pathway in prostate cancer and that manipulation of ARF1 expression unlikely alters the activation of the PI3K-AKT pathway as defined in breast cancer cells [21].